30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis

• Enrique M. Ocio,
• Aurore Perrot,
• Philippe Moreau,
• Maria‐Victoria Mateos,
• Sara Bringhen,
• Joaquín Martínez‐López,
• Lionel Karlin,
• Song‐Yau Wang,
• Corina Oprea,
• Yi Li,
• Ercem Kodas,
• Jesus San‐Miguel

Affiliations

Enrique M. Ocio

Servicio de Hematología y Hemoterapia, Hospital Universitario Marqués de Valdecilla University Hospital (IDIVAL) Universidad de Cantabria Santander Spain

Aurore Perrot

Service d'Hématologie, CHU de Toulouse, IUCT‐O Université de Toulouse Toulouse France

Philippe Moreau

Department of Hematology University of Nantes Nantes France

Maria‐Victoria Mateos

Department of Hematology University Hospital of Salamanca and Cancer Research Center (IBMCC‐CSICUSAL) Salamanca Spain

Sara Bringhen

Department of Onco‐Ematologia e Myeloma Multiplo, SSD Clinical Trials AOU Città della Salute e della Scienza di Torino Italy

Joaquín Martínez‐López

Department of Hematology Hospital Universitario 12 de Octubre, CNIO, Universidad, Complutense de Madrid Spain

Lionel Karlin

Service d'Hématologie Clinique, Hôpital Lyon Sud Hospices Civils de Lyon Pierre‐Bénite France

Song‐Yau Wang

Department of Hematology and Oncology University of Leipzig Leipzig Germany

Corina Oprea

Research and Development, Sanofi Vitry‐sur‐Seine France

Yi Li

Research and Development, Sanofi Bejing China

Ercem Kodas

Research and Development, Sanofi Vitry‐sur‐Seine France

Jesus San‐Miguel

Department of Clinical and Translational Medicine University of Navarra (CCUN), Center for Applied Medical Research (CIMA), IDISNA, CIBERONC Pamplona Spain